In the preceding three months, 14 analysts have released ratings for Phreesia (NYSE:PHR), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 7 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 5 | 5 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Phreesia, revealing an average target of $29.14, a high estimate of $35.00, and a low estimate of $24.00. A decline of 11.02% from the prior average price target is evident in the current average.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Phreesia by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Alexei Gogolev | JP Morgan | Lowers | Overweight | $24.00 | $29.00 |
| Clark Wright | DA Davidson | Lowers | Buy | $30.00 | $35.00 |
| Daniel Grosslight | Citigroup | Lowers | Buy | $25.00 | $29.00 |
| Stan Berenshteyn | Wells Fargo | Announces | Overweight | $30.00 | - |
| Glen Santangelo | Barclays | Lowers | Overweight | $24.00 | $26.00 |
| Steven Valiquette | Mizuho | Lowers | Outperform | $28.00 | $36.00 |
| Joseph Vruwink | Baird | Lowers | Outperform | $25.00 | $31.00 |
| Daniel Grosslight | Citigroup | Lowers | Buy | $29.00 | $34.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $35.00 | $35.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $33.00 | $38.00 |
| Alexei Gogolev | JP Morgan | Lowers | Overweight | $29.00 | $32.00 |
| Glen Santangelo | Barclays | Announces | Overweight | $26.00 | - |
| Ryan MacDonald | Needham | Maintains | Buy | $35.00 | $35.00 |
| Clark Wright | DA Davidson | Raises | Buy | $35.00 | $33.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Phreesia compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Phreesia's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Phreesia's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Phreesia analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Phreesia
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
Financial Milestones: Phreesia's Journey
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Phreesia's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.67% as of 31 October, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Phreesia's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Phreesia's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.38% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Phreesia's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: Phreesia's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!